Eliana Merle
Stock Analyst at UBS
(0.92)
# 2184
Out of 5,354 analysts
97
Total ratings
40.43%
Success rate
-0.18%
Average return
Main Sectors:
Top Industries:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
RAPT RAPT Therapeutics | Maintains: Neutral | 2 1 | 1.03 | -2.91% | 3 | May 22, 2025 | |
ARVN Arvinas | Maintains: Buy | 74 21 | 6.93 | 203.03% | 4 | May 15, 2025 | |
KYMR Kymera Therapeutics | Maintains: Buy | 72 70 | 44.92 | 55.83% | 3 | May 13, 2025 | |
MRNA Moderna | Maintains: Buy | 78 70 | 27.15 | 157.83% | 7 | May 2, 2025 | |
MDGL Madrigal Pharmaceuti... | Maintains: Strong Buy | 441 458 | 283.63 | 61.48% | 4 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 13 12 | 4.45 | 169.66% | 2 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 65 72 | 37.72 | 90.88% | 3 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 44 | 18.56 | 137.07% | 8 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 109 113 | 56.67 | 99.4% | 2 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 25 38 | 10.15 | 274.38% | 3 | Jan 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 42 109 | 53.07 | 105.39% | 4 | Jan 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 5 3 | 1.45 | 51.72% | 4 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 65 71 | 39.95 | 77.72% | 2 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 196 | 174.97 | 12.02% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 28 | 10.15 | 175.86% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 12 | 4.11 | 191.97% | 1 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Neutral | 3 | 3.61 | -16.9% | 1 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 26 | 5.51 | 371.87% | 1 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 23 33 | 20.89 | 57.97% | 4 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 97 131 | 111.93 | 17.04% | 6 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 253 288 | 304.63 | -5.46% | 1 | Jun 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 3 5 | 4.08 | 22.55% | 3 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 19 18 | 3.47 | 418.73% | 2 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 25 33 | n/a | n/a | 7 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 45 42 | 15.08 | 178.51% | 4 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 34 40 | n/a | n/a | 2 | May 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 19 8 | 1.25 | 540% | 2 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 22 | 4.63 | 375.16% | 1 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 51 47 | 10.19 | 361.24% | 1 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 9 | n/a | n/a | 1 | May 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 16 | 6.19 | 158.48% | 2 | May 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 192 134 | 28.64 | 367.88% | 3 | Aug 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Neutral | 121 | n/a | n/a | 1 | Apr 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 10 | n/a | n/a | 1 | Jan 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 57 68 | n/a | n/a | 2 | Oct 22, 2018 |